In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations
- PMID: 20409341
- PMCID: PMC2873490
- DOI: 10.1186/1471-2180-10-119
In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations
Abstract
Background: Fluoroquinolones are potent antimicrobial agents used for the treatment of a wide variety of community- and nosocomial- infections. However, resistance to fluoroquinolones in Enterobacteriaceae is increasingly reported. Studies assessing the ability of fluoroquinolones to select for resistance have often used antimicrobial concentrations quite different from those actually acquired at the site of infection. The present study compared the ability to select for resistance of levofloxacin, ciprofloxacin and prulifloxacin at concentrations observed in vivo in twenty strains of Escherichia coli and Klebsiella spp. isolated from patients with respiratory and urinary infections. The frequencies of spontaneous single-step mutations at plasma peak and trough antibiotic concentrations were calculated. Multi-step selection of resistance was evaluated by performing 10 serial cultures on agar plates containing a linear gradient from trough to peak antimicrobial concentrations, followed by 10 subcultures on antibiotic-free agar. E. coli resistant strains selected after multi-step selection were characterized for DNA mutations by sequencing gyrA, gyrB, parC and parE genes.
Results: Frequencies of mutations for levofloxacin and ciprofloxacin were less than 10-11 at peak concentration, while for prulifloxacin they ranged from <10-11 to 10-5. The lowest number of resistant mutants after multistep selection was selected by levofloxacin followed by ciprofloxacin and prulifloxacin. Both ciprofloxacin- and prulifloxacin-resistant mutants presented mutations in gyrA and parC, while levofloxacin resistance was found associated only to mutations in gyrA.
Conclusions: Among the tested fluoroquinolones, levofloxacin was the most capable of limiting the occurrence of resistance.
Figures

Similar articles
-
In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations.J Antimicrob Chemother. 2009 Apr;63(4):721-7. doi: 10.1093/jac/dkp020. Epub 2009 Feb 13. J Antimicrob Chemother. 2009. PMID: 19218275
-
In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.Int J Antimicrob Agents. 2007 Jun;29(6):679-87. doi: 10.1016/j.ijantimicag.2007.01.009. Epub 2007 Mar 23. Int J Antimicrob Agents. 2007. PMID: 17363225
-
Risk factors and mechanisms of fluoroquinolone resistance in 156 Escherichia coli strains clinically isolated from urinary tract infections.Scand J Infect Dis. 2011 Feb;43(2):83-8. doi: 10.3109/00365548.2010.526632. Epub 2010 Oct 14. Scand J Infect Dis. 2011. PMID: 20942776
-
Escherichia coli Resistance to Fluoroquinolones in Community-Acquired Uncomplicated Urinary Tract Infection in Women: a Systematic Review.Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00862-20. doi: 10.1128/AAC.00862-20. Print 2020 Sep 21. Antimicrob Agents Chemother. 2020. PMID: 32747356 Free PMC article.
-
The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.Front Public Health. 2022 Dec 21;10:1025633. doi: 10.3389/fpubh.2022.1025633. eCollection 2022. Front Public Health. 2022. PMID: 36620240 Free PMC article. Review.
Cited by
-
Dynamics of quinolone resistance in fecal Escherichia coli of finishing pigs after ciprofloxacin administration.J Vet Med Sci. 2014 Sep;76(9):1213-8. doi: 10.1292/jvms.14-0025. Epub 2014 Jun 12. J Vet Med Sci. 2014. PMID: 24919413 Free PMC article.
-
Increased multi-drug resistant Escherichia coli from hospitals in Khartoum state, Sudan.Afr Health Sci. 2012 Sep;12(3):368-75. doi: 10.4314/ahs.v12i3.19. Afr Health Sci. 2012. PMID: 23382754 Free PMC article.
-
Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice-The "AIOLOS" Study.Can Respir J. 2021 May 25;2021:6620585. doi: 10.1155/2021/6620585. eCollection 2021. Can Respir J. 2021. PMID: 34122678 Free PMC article.
-
Cumulative clinical experience from over a decade of use of levofloxacin in urinary tract infections: critical appraisal and role in therapy.Infect Drug Resist. 2011;4:177-89. doi: 10.2147/IDR.S15610. Epub 2011 Oct 18. Infect Drug Resist. 2011. PMID: 22114510 Free PMC article.
-
Genomic alterations involved in fluoroquinolone resistance development in Staphylococcus aureus.PLoS One. 2023 Jul 26;18(7):e0287973. doi: 10.1371/journal.pone.0287973. eCollection 2023. PLoS One. 2023. PMID: 37494330 Free PMC article.
References
-
- Luzzaro F, Viganò EF, Fossato D, Grossi A, Sala A, Sturla C, Saudelli M, Toniolo A. AMCLI Lombardia Hospital Infectious Study Group. Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two years study in 16 hospitals. Eur J Clin Microbiol Infect Dis. 2002;21:849–855. - PubMed
-
- Kang CI, Kim SH, Bang JW, Kim HB, Kim NJ, Kim EC, Oh MD, Choe KW. Community-acquired versus nosocomial Klebsiella pneumoniae bacteriemia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance. J Korean Med Sci. 2006;21:816–822. doi: 10.3346/jkms.2006.21.5.816. - DOI - PMC - PubMed
-
- Gobernado M, Valdes L, Alos JI, García Rey C, Dal-Ré Saavedra R, García de Lomas J. Quinolone resistance in female outpatient urinary tract isolates of Escherichia coli: age-related differences. Rev Esp Quimioterap. 2007;20:206–210. - PubMed
-
- Andreu A, Alos JI, Gobernado M, Marco F, de la Rosa M, García-Rodríguez JA, García-Rodríguez JA. Grupo Cooperativo Español para el Estudio de la Sensibilidad Antimicrobiana de los Patógenos Urinarios. Etiology and antimicrobial susceptibility among uropathogens causing community-acquired urinary tract infections: a nationwide surveillance study. Enferm Infec Microbiol Clin. 2005;23:4–9. doi: 10.1157/13070401. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous